NCT06735898
Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 14 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Dec 1, 2025 to May 1, 2026
- Study completion date changed from estimate of May 1, 2026 to Sep 1, 2026
- Site details revised
- Notable Primary completion date: Mar 1, 2025 to Dec 1, 2025
- Study completion date: Sep 1, 2025 to May 1, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Dynamics of rehabilitation routing status score
Timeframe: day 12, day 30, day 60, day 90
Dynamics of Barthel status score
Timeframe: day 12, day 30, day 60, day 90
Dynamics of EQ5 status score
Timeframe: day 12, day 30, day 60, day 90
Secondary (2)
Dynamics of somatic status
Dynamics of rehabilitation status
Arms and interventions
Group 1
Basic therapy + Cytoflavin® intravenous solution in the volume of 20 ml per day IV drip in dilution on 100-200 ml of 5-10% dextrose solution or 0.9% sodium chloride solution during 10 days, transition to Cytoflavin® tablets from the next day after the end of intravenous administration during the next 75 days according to the instructions for medical use
Group 2
Basic therapy, according to clinical guidelines (clinical practice established within the center) for the treatment of patients in stages 2-3 of rehabilitation.
Sites
1 site in 1 country
- Brain Institute ClinicYekaterinburg, Sverdlovsk Oblast, Russia